ATE427311T1 - (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen - Google Patents

(r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen

Info

Publication number
ATE427311T1
ATE427311T1 AT05791212T AT05791212T ATE427311T1 AT E427311 T1 ATE427311 T1 AT E427311T1 AT 05791212 T AT05791212 T AT 05791212T AT 05791212 T AT05791212 T AT 05791212T AT E427311 T1 ATE427311 T1 AT E427311T1
Authority
AT
Austria
Prior art keywords
sub
rifamycin derivatives
preparation
humans
pharmaceutical compositions
Prior art date
Application number
AT05791212T
Other languages
English (en)
Inventor
Charles Ding
Zhenkun Ma
Jing Li
Susan Harran
Yong He
Keith Minor
In Kim
Jamie Longgood
Yafei Jin
Keith Combrink
Original Assignee
Cumbre Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumbre Pharmaceuticals Inc filed Critical Cumbre Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE427311T1 publication Critical patent/ATE427311T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT05791212T 2004-07-22 2005-07-21 (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen ATE427311T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59019004P 2004-07-22 2004-07-22

Publications (1)

Publication Number Publication Date
ATE427311T1 true ATE427311T1 (de) 2009-04-15

Family

ID=35355764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05791212T ATE427311T1 (de) 2004-07-22 2005-07-21 (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (2) US7229996B2 (de)
EP (2) EP1781670A1 (de)
JP (2) JP5236944B2 (de)
CN (2) CN101065385A (de)
AT (1) ATE427311T1 (de)
AU (1) AU2005267054B2 (de)
CA (2) CA2574307A1 (de)
DE (1) DE602005013671D1 (de)
NZ (1) NZ565002A (de)
WO (2) WO2006012443A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
EP1693364B1 (de) * 2003-12-12 2015-05-20 Daiichi Sankyo Company, Limited Zwischenprodukte für die herstellung von optisch aktiven cyclopropylaminderivaten und verfahren zur herstellung der zwischenprodukte
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations
US8404664B2 (en) 2005-08-11 2013-03-26 Targanta Therapeutics, Inc. Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections
US7892826B2 (en) 2005-08-15 2011-02-22 Janssen Pharmaceutica N.V. Human cell clones having an endogeneous urotensin II receptor
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2009064792A1 (en) * 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Quinolone carboxylic acid-substituted rifamycin derivatives
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US20110071180A1 (en) * 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
US8278313B2 (en) * 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8524691B2 (en) 2008-08-13 2013-09-03 The Medicines Company Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
CN101875658B (zh) * 2009-04-28 2013-01-09 上海药明康德新药开发有限公司 3-羰基-2,8-二氮杂螺[4.5] 癸烷-8-羧酸叔丁酯的制备方法
ME03452B (de) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disubstituierte octahy-dropyrrolo [3,4-c]pyrrole als orexinrezeptormodulatoren
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN104736152B (zh) * 2012-08-13 2018-01-23 阿迪帕姆单人股份公司 包含3‑甲酰基利福霉素sv和3‑甲酰基利福霉素s的3‑(4‑肉桂基‑1‑哌嗪基)氨基衍生物的药物制剂以及它们的制备方法
CA2886264A1 (en) * 2012-09-12 2014-03-20 Salix Pharmaceuticals, Inc. Methods of administering rifaximin without producing antibiotic resistance
CN103709177B (zh) * 2013-12-20 2016-02-24 武汉工程大学 利福霉素类沃尼妙林杂合抗生素及其制备方法
CN104710439B (zh) * 2015-03-06 2017-11-07 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的晶型i及其制备方法
CN104628745B (zh) * 2015-03-06 2017-03-08 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的富马酸盐及其制备方法
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
CN105879009A (zh) * 2016-04-18 2016-08-24 丹诺医药(苏州）有限公司 一种用于治疗革兰氏阴性菌感染的抗菌药物组合物
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
CN106902116B (zh) * 2017-02-28 2021-03-23 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮双靶标分子的应用
CN106822125A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的新用途
CN109251258B (zh) * 2017-07-13 2021-06-01 中国石油天然气股份有限公司 宽分布聚丙烯催化组分、组分制备方法及其催化剂
CN110944999A (zh) 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
EP3501496A1 (de) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Flüssigkeitsabgabezusammensetzung
CN108310393A (zh) * 2018-02-12 2018-07-24 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的应用
CN109529045B (zh) * 2019-01-08 2021-05-18 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其药学上可接受的盐的应用
CN109464673A (zh) * 2019-01-08 2019-03-15 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其盐的应用和制剂
CN109942474B (zh) * 2019-03-04 2020-09-18 华中科技大学 一种邻叠氮-肼类化合物及其制备方法
CN115501230B (zh) * 2022-08-05 2023-11-21 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子软膏剂及其制备方法
AU2023450551A1 (en) * 2023-05-29 2026-01-22 Tennor Therapeutics (Suzhou) Limited Joint cavity drug administration method, and use thereof
WO2024254840A1 (zh) * 2023-06-16 2024-12-19 丹诺医药(苏州）有限公司 化合物治疗疾病的方法及其用途
WO2024254841A1 (zh) * 2023-06-16 2024-12-19 丹诺医药(苏州）有限公司 化合物治疗疾病的方法及其用途
WO2025167866A1 (zh) * 2024-02-07 2025-08-14 丹诺医药（苏州）股份有限公司 化合物的固体分散体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293503C (en) * 1988-03-18 1991-12-24 Fumihiko Kanoo Substituted benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP3566962B2 (ja) * 1993-05-24 2004-09-15 アベンテイス・バルク・ソチエタ・ペル・アチオニ リファマイシンの３６−誘導体
US7122525B2 (en) * 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
EP1723150A1 (de) 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Gegen arzneimittel resistente mikrobenwirksame rifamyciniminoderivate
WO2005070940A2 (en) 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes

Also Published As

Publication number Publication date
JP2008507549A (ja) 2008-03-13
US7226931B2 (en) 2007-06-05
JP5153329B2 (ja) 2013-02-27
CA2574301C (en) 2013-09-10
HK1102808A1 (en) 2007-12-07
US20060019986A1 (en) 2006-01-26
JP5236944B2 (ja) 2013-07-17
AU2005267054B2 (en) 2011-06-23
EP1768987B1 (de) 2009-04-01
JP2008507548A (ja) 2008-03-13
WO2006012470A1 (en) 2006-02-02
CA2574301A1 (en) 2006-02-02
EP1781670A1 (de) 2007-05-09
WO2006012443A1 (en) 2006-02-02
NZ565002A (en) 2009-08-28
CN101031572A (zh) 2007-09-05
EP1768987A1 (de) 2007-04-04
AU2005267054A1 (en) 2006-02-02
DE602005013671D1 (de) 2009-05-14
US7229996B2 (en) 2007-06-12
CN101031572B (zh) 2010-12-08
CA2574307A1 (en) 2006-02-02
US20060019985A1 (en) 2006-01-26
CN101065385A (zh) 2007-10-31

Similar Documents

Publication Publication Date Title
DE602005013671D1 (de) (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
AUPR213700A0 (en) Antiviral agents
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
CO5280078A1 (es) Compuestos
WO2008108386A1 (ja) 医薬組成物
EP2266623A3 (de) Prodrugs mit neuen biospaltbaren Verbindern
AU2003222106A1 (en) Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
TW200628161A (en) Novel betulin derivatives, preparation thereof and use thereof
EP1362846A4 (de) Aminoethanolderivate
EP2266622A3 (de) Prodrugs mit neuen biospaltbaren Verbindern
EP1340755A4 (de) Mittel mit wirkung gegen helicobacter
TW200745153A (en) Trehalose compound and pharmaceutical comprising the compound
TW200630378A (en) Macrolones-amino substituted quinolones
GB201115158D0 (en) Improvements in and realating to biocidal compositions
WO2002020525A3 (en) Protein tyrosine phosphatase inhibitor
EP1813270A4 (de) Proteininhibitoren der hsp90-familie
AU2001282871A1 (en) Antithrombotic agents
BRPI0416708A (pt) derivados de aminoquinazolidinadiona antibacterianos
TR200200550T2 (tr) Piruvat dehidrojenaz aktivitesini yükselten ikameli n-fenil 2-hidroksi -2- metil -3,3,3- triflüoropropanamid türevleri.
MY140325A (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
MY133397A (en) Novel crystalline forms of a macrolide antibiotic
CA2386772A1 (en) Pentacyclic taxane compound
AU2003294031A1 (en) Dust-free pigment compositions obtainable by spray-drying
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
DE60112769D1 (de) Tetraphenylbacteriochlorin-derivate und diese enthaltenden zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties